Home >> Marketplace Archives >> Thermo Fisher inks deal to expand Oncomine Dx

Thermo Fisher inks deal to expand Oncomine Dx

Print Friendly, PDF & Email


June 2018—Thermo Fisher Scientific has signed agreements with Daiichi Sankyo and Takeda Pharmaceuticals designed to expand the clinical utility of Oncomine Dx Target Test in support of clinical trials and drug development programs at the Japanese companies. The agreements will focus on validating additional biomarkers and gene variants on the test. Under the terms of the agreements, Thermo Fisher will retain worldwide commercialization rights for the test and will lead all filings of supplemental premarket approvals to seek FDA approval.

Oncomine Dx Target Test is FDA approved to simultaneously report 23 genes clinically associated with NSCLC. Of those 23, three contain markers that are approved for use as a companion diagnostic for specific targeted therapies. Since receiving FDA approval last year, Oncomine Dx Target Test has received positive reimbursement decisions from the Centers for Medicare and Medicaid Services and from large commercial health insurers.

Thermo Fisher Scientific, 800-955-6288


Check Also

Thermo Fisher acquires IntegenX, 5/18

May 2018—Thermo Fisher Scientific has acquired IntegenX, a forensic DNA testing firm. IntegenX products include the RapidHIT platforms, software analysis tools, and related consumables that are compatible with Thermo Fisher’s short tandem repeat chemistries for human identification.